Here’s a breakdown of the article excerpt, summarizing the key points about the Toronto Blue Jays’ signing of pitcher Andrew Enright:
* Enright’s Situation: Andrew Enright was designated for assignment by the Cleveland Guardians after undergoing tommy John surgery in October. This means he’ll miss the entire 2026 season.
* Blue Jays’ Prospect: Most teams would have likely dropped Enright,but the Blue Jays saw potential in him despite the long recovery.
* The Deal: Toronto signed Enright to a two-year minor league deal. This provides him financial security and allows him to rehab without pressure.
* Low Risk, High Reward: The Blue Jays get a potential bullpen arm for 2027 at a minimal cost. It’s also seen as a positive move to support a player who has already faced adversity.
* Enright’s Potential: he showed promise in his MLB debut with a good fastball-slider combination and a high strikeout rate.
* Bullpen Depth: The Blue Jays have already added pitching (Dylan Cease and Cody Ponce), but recognize the importance of depth throughout a long season. If Enright recovers well, he could be a valuable addition to the bullpen.
In essence, the Blue jays are making a calculated gamble on a pitcher with potential, offering him a supportive environment to recover from a major injury.
